CareDx (NASDAQ:CDNA - Get Free Report)'s stock had its "neutral" rating reiterated by stock analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $25.00 price objective on the stock. HC Wainwright's price target indicates a potential upside of 66.67% from the company's current price.
Several other analysts have also weighed in on CDNA. Stephens reiterated an "overweight" rating and set a $40.00 target price on shares of CareDx in a research note on Thursday, February 27th. StockNews.com raised shares of CareDx from a "hold" rating to a "buy" rating in a research report on Wednesday, February 26th. Wells Fargo & Company raised shares of CareDx from an "underweight" rating to an "equal weight" rating and cut their target price for the stock from $28.00 to $24.00 in a report on Wednesday, January 15th. Finally, The Goldman Sachs Group lowered their target price on CareDx from $34.00 to $26.00 and set a "buy" rating for the company in a report on Thursday, April 17th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $30.33.
Read Our Latest Analysis on CDNA
CareDx Price Performance
Shares of CDNA stock opened at $15.00 on Monday. The firm has a fifty day moving average of $18.49 and a two-hundred day moving average of $21.42. The firm has a market cap of $835.22 million, a P/E ratio of -5.56 and a beta of 2.27. CareDx has a 1-year low of $9.64 and a 1-year high of $34.84.
CareDx (NASDAQ:CDNA - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The company reported $0.09 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.03. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The business had revenue of $84.69 million during the quarter, compared to the consensus estimate of $84.56 million. During the same period last year, the firm earned ($0.03) earnings per share. The company's revenue for the quarter was up 17.6% compared to the same quarter last year. On average, sell-side analysts expect that CareDx will post -0.9 EPS for the current year.
Insider Activity at CareDx
In other CareDx news, Director Peter Maag sold 13,281 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $17.23, for a total value of $228,831.63. Following the sale, the director now owns 316,743 shares in the company, valued at approximately $5,457,481.89. This trade represents a 4.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.90% of the stock is currently owned by insiders.
Institutional Trading of CareDx
Several large investors have recently added to or reduced their stakes in the business. Victory Capital Management Inc. acquired a new position in CareDx during the 1st quarter worth $1,329,000. CWM LLC lifted its holdings in CareDx by 23.0% in the first quarter. CWM LLC now owns 12,413 shares of the company's stock worth $220,000 after purchasing an additional 2,319 shares during the period. Calamos Advisors LLC grew its position in CareDx by 65.0% in the 1st quarter. Calamos Advisors LLC now owns 143,989 shares of the company's stock valued at $2,556,000 after buying an additional 56,724 shares in the last quarter. Principal Financial Group Inc. increased its stake in CareDx by 3.4% during the 1st quarter. Principal Financial Group Inc. now owns 19,624 shares of the company's stock valued at $348,000 after buying an additional 640 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its position in shares of CareDx by 32.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 432,035 shares of the company's stock worth $7,669,000 after buying an additional 104,692 shares in the last quarter.
CareDx Company Profile
(
Get Free Report)
CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CareDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.
While CareDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
